• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Glob Health . Severe, primary, and incidental COVID-19 in hospitalised children, South Africa: 2020-2023

tetano

Editor, Senior Moderator
J Glob Health


. 2026 Jan 30:16:04009.
doi: 10.7189/jogh.16.04009.
Severe, primary, and incidental COVID-19 in hospitalised children, South Africa: 2020-2023

Ameena Goga[SUP] 1 2 [/SUP], Trisha Ramraj[SUP] 1 [/SUP], Jeané Cloete[SUP] 2 3 4 [/SUP], Dini Mawela[SUP] 5 [/SUP], Zainab Waggie[SUP] 6 [/SUP], Moherndran Archary[SUP] 7 [/SUP], Kogielambal Chinniah[SUP] 7 [/SUP], Prakash Jeena[SUP] 7 [/SUP], Nomakhuwa E Tabane[SUP] 8 [/SUP], Riana Van Zyl[SUP] 8 [/SUP], Gary Reubenson[SUP] 9 [/SUP], Renate Strehlau[SUP] 9 [/SUP], Ute Feucht[SUP] 2 3 4 [/SUP], Tarylee Reddy[SUP] 10 [/SUP], Nobuhle Mchunu[SUP] 10 [/SUP], Shannon Cawood[SUP] 11 [/SUP], Liesl Zühlke[SUP] 12 13 [/SUP], Kate Webb[SUP] 14 [/SUP], Heather J Zar[SUP] 15 16 [/SUP], Kirsten A Donald[SUP] 17 [/SUP], Christiaan Scott[SUP] 14 18 [/SUP], Brenda M Morrow[SUP] 15 [/SUP], Thomas Aldersley[SUP] 13 [/SUP], Nicolette M du Plessis[SUP] 2 3 4 [/SUP], Terusha Chetty[SUP] 1 19 [/SUP], Sithembiso Velaphi[SUP] 6 [/SUP], Ziyaad Dangor[SUP] 6 20 [/SUP], David P Moore[SUP] 6 20 [/SUP]


Affiliations
Abstract

Background: Knowledge gaps persist regarding paediatric COVID-19 clinical presentation, treatment and outcomes in high HIV prevalence settings, with low COVID-19 vaccine coverage.
Methods: An ambi-directional cohort study was conducted in 13 South African public sector hospitals. Hospitalised children with SARS-CoV-2 infection or post-infection syndrome were included. Main outcomes measures included severe disease and primary COVID-19 (hospitalisation for SARS-CoV-2 infection).
Results: There were 2363 SARS-CoV-2 positive children included (March 2020 through May 2023); median age 23.6 months (interquartile range (IQR) = 4.3-98.2 months). Excluding missing values, 1618 (68.9%) children had primary COVID-19; 1121 (69.3%) of these had severe primary COVID-19. In the primary COVID-19 group with data, 318 / 1588 (20.0%) received intensive or high care, 121/1285 (9.4%) received a blood transfusion and 48/1616 (3.0%) died. Multivariable analyses demonstrated that severe primary COVID-19 was 32% higher in children aged 29-365 days (adjusted Risk Ratio (aRR) = 1.32 (95% confidence interval (CI) = 1.13-1.55); reference: 0-28 days), 13% higher with one or more comorbidities (aRR = 1.13; CI = 1.05-1.22)), and 14-22% lower during the Beta, Delta and Omicron periods (reference: ancestral period). Amongst all hospitalised children with a positive SARS-CoV-2 test, severe disease was commoner in underweight children (aRR 1.09; CI = 1.02-1.17, P = 0.013)). Severe signs were commoner in children living with HIV (CLHIV), 88/121 (72.7%), vs. HIV uninfected 1320 / 2104 (62.7%), P = 0.026, and in antiretroviral therapy-naïve CLHIV, (37 / 41 (90.2%), vs. CLHIV on therapy 51 / 80 (63.8%), P = 0.002).
Conclusions: In a high HIV prevalence country, approximately 70% of children with a positive SARS-CoV-2 test were hospitalised for COVID-19 treatment; almost 70% of these children were severely ill. Controlling for other factors, disease severity was highest in the hypothesised pre-immunity Ancestral period. HIV infection and delayed ART initiation were associated with severe signs. In such settings, strengthening general child health programmes to reduce underweight and prevent or treat paediatric HIV may reduce the severity of new diseases of pandemic proportion.


 
Back
Top Bottom